AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

Suggested remit: To appraise the clinical and cost effectiveness of mirvetuximab soravtansine within its marketing authorisation for treating folate receptor alpha-positive platinum-resistant advanced ...

Looking for medication to treat folate-receptor-alpha-positive-epithelial-ovarian-cancer? Find a list of current medications, their possible side effects, dosage, and efficacy when used to treat ...

Treatment with Elahere (mirvetuximab soravtansine-gynx) showed consistent survival benefits in a long-term analysis from the phase 3 trial MIRASOL evaluating patients with folate receptor ...

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic ...

SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha ...

This is a Phase 1/2 study of PRO1184, a folate receptor-alpha- (FRα) targeted antibody-drug conjugate, to evaluate the safety, tolerability, PK, and antitumor activity of PRO1184 in patients with ...

--Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha to its Precise™ Oncology Solutions portfolio. "FRα, alongside ...